Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors

New diacylhydrazine derivatives have been designed and evaluated for their PLK1 inhibitory activity and anti-cervical cancer cell activity. The most active compound is 7k.